Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
Tóm tắt
Từ khóa
Tài liệu tham khảo
Liaw Y F, 2003, Asian‐Pacific consensus statement on the management of chronic hepatitis B, an update, 18, 239
EASL J u r y., 2003, EASL international consensus conference on hepatitis B, consensus statement, 38, 533
Lok A S F, 2004, Chronic hepatitis B, update of recommendation, 39, 857
Yokosuka O, 1985, Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment, analysis of intrahepatic replicative hepatitis B virus DNA, 5, 728
Liaw Y F., 2003, Hepatitis flares and hepatitis B e antigen seroconversion, implication in anti-hepatitis B virus therapy, 18, 246
Lai M Y, 1988, Reactivation of hepatitis B virus in anti‐HBe‐positive chronic active type B hepatitis, molecular and immunohistochemical studies, 35, 17
Liaw Y F, 1988, The development of cirrhosis in patients with chronic type B hepatitis, a prospective study, 8, 493
Liaw Y F, 1989, Natural course after the development of cirrhosis in patients with chronic type B hepatitis, a prospective study, 9, 235
Tsai S L, 1988, Natural history of hepatitis B surface antigen‐positive cirrhosis in Taiwan, a clinicopathological study, 3, 583
Yuen M F, 2004, HBsAg seroclearance in chronic hepatitis B in the Chinese, virological, histological, and clinical aspects, 39, 1694
Kao J H., 2002, Hepatitis B viral genotypes, clinical relevance and molecular characteristics, 17, 643
Fung S K, 2004, Hepatitis B virus genotypes, do they play a role in the outcome of HBV infection?, 40, 790
Chu C J, 2003, Hepatitis B virus genotypes in the United States, results of a nationwide study, 125, 444
Liaw Y F, 1994, Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians, a randomised controlled trial, 20, 175
Janssen H L, 1999, Interferon alfa for chronic hepatitis B infection, increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP), 30, 238
Perillo R P., 1995, Chronic hepatitis B problem patients (including patients with decompensated disease), J Hepatology, 22, 45
Brunetto M R, 2002, The outcome of chronic anti–HBe positive chronic hepatitis B in alpha interferon treated and untreated patients, a long term cohort study, 36, 263
Cooksley W G F, 2003, Peginterferon alpha 2a(40 kDa), an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B, 10, 298
Janssen H L A, 2005, Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B, a randomised trial, 365, 123
Lau G K K, 2004, Peginterferon alfa‐2A (40KD) (Pegasys®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg‐positive chronic hepatitis B, results from a large, multinational study, 40, 171A
Wai C T, 2002, HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C, Hepatology, 36, 1425
Schalm S W, 2000, Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection, a randomised trail, 46, 562
Santantonio T, 2002, Lamivudine/interferon combination therapy in anti‐HBe positive chronic hepatitis B patients, a controlled pilot study, 36, 799
Akarca U S, 2004, Interferon–lamivudine combination is no better than lamivudine alone in anti‐HBe‐positive chronic hepatitis B, Antivir Ther, 9, 325, 10.1177/135965350400900306
Chan H L, 2005, A randomized, controlled trial of combination therapy for chronic hepatitis B, comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone, 142, 240
Chien R N, 1998, Efficacy of thymosin α1 in patients with chronic type B hepatitis, a randomized controlled trial, 27, 1383
Chan H L, 2001, The efficacy of thymosin in the treatment of chronic hepatitis B virus infection, a meta-analysis, 15, 1899
Guan R, 2001, Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B, J Gastroenterol Hepatol, 16, A60
Yao G B, 2004, A 3‐year clinical trial of lamivudine in treatment of patients with chronic hepatitis B, Hepatobiliary Pancreat Dis Int, 3, 188
Leung N W, 2001, Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates, results after 3 years of therapy, 33, 1527
Sung J J Y, 2003, A randomized double‐blind Phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB), week 52 analysis, 38, 25
Yang H, 2004, In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase, J Hepatol, 40, A
Perillo R, 2004, Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant and a reduced response to lamivudine, 2 year results, 40, A
Lim Y S, 2004, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivdudine resistant decompensated liver disease, J Gastroenterol Hepatol, 19, A868
Chang T T, 2004, Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B, results of phase III study in nucleoside-naive patients, 40, 193A
Shouval D, 2004, Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside‐naive HbeAg(‐) chronic hepatitis B, results of phase III trial, 40, 728A
Shermman M, 2004, Entecavir is superior to continued lamivudine for the treatment of lamivudine refractory, HBeAg (+) chronic hepatitis B, results of phase III study, 40, 664A
Liaw Y F, 2004, Lamivudine‐refractory chronic hepatitis B patients cane be safely switched to entecavir 1.0 mg daily without risk of ALT flare, J Gastroenterol Hepatol, 19, A676
Lee K S, 2004, A 12‐week clevudine therapy showed durable antiviral activity and normalization of alanine transminase levels for 6 months after discontinuation of treatment in patients with chronic hepatitis B, Hepatology, 40, 652A
McCulloch M, 2002, Chinese herbal medicine and interferon in the treatment of chronic hepatitis B, a meta-analysis of randomized, controlled trials, 92, 1619
Thio C L, 2002, Multicenter AIDS Cohort Study, HIV-1, hepatitis B virus, and risk of liver related mortality in the Multicenter Cohort Study (MACS), 360, 1921
Farci P, 2004, Long‐term benefit of interferon alpha therapy of chronic hepatitis D, regression of advanced hepatic fibrosis, 126, 1740
Wong D K, 1995, Interferon alfa treatment of chronic hepatitis B, randomized trial in a predominantly homosexual male population, 108, 165
Zylberberg H, 1996, Alpha‐interferon for chronic active hepatitis B in human immunodeficiency virus‐infected patients, Gastroenterol Clin Biol, 20, 968
Hui J M, 2002, Changes in serum albumin during treatment of chronic hepatitis B with lamivudine, effects of response and emergence of drug resistance, 97, 1003
Chang T T, 2003, Long tern safety of adfovir dipivoxil (ADV) in 10 mg once daily for chronic hepatitis B (CHB), an integrated analysis of two phase III studies (abs), 38, 133
Australian and New Zealand Liver Transplant Registry 13th Report. 2001 (http://www.cs.nsw.gov.au/Gastro/LiverTransplant/default.htm)
Dusheiko G M, 1995, Treatment of chronic type B and C hepatitis with interferon alfa, an economic appraisal, 22, 1863
O'Grady J G., 1997, Clinical economics review, liver transplantation, 11, 445
Burroughs A, 1992, Comparative hospital costs of liver transplantation and the treatment of complications of cirrhosis, Eur J Gastrol, 4, 123
Sharma P, 2004, A critical review of the diagnosis and management of Barrett's esophagus, the AGA Chicago Workshop, 127, 310
Liaw Y F, 2004, No benefit to continue lamivudine therapy after emergence of YMDD mutations, Antivir Ther, 9, 257, 10.1177/135965350400900208